News

Article

Orasis Pharmaceuticals’ prescription pilocarpine hydrochloride ophthalmic solution 0.4% (Qlosi) for presbyopia available in the US

Key Takeaways

  • Qlosi eye drops offer a novel presbyopia treatment, enhancing near vision with flexible dosing and minimal side effects.
  • The EyeQ formulation balances pilocarpine concentration and pH for optimal efficacy and safety.
SHOW MORE

The novel corrective eye drop can be prescribed through pharmacy partners BlinkRx or Medvantx

(Image credit: AdobeStock/auremar)

(Image credit: AdobeStock/auremar)

Orasis Pharmaceuticals announced that its novel corrective eye drop for the treatment of presbyopia in adults (Qlosi; pilocarpine hydrochloride ophthalmic solution 0.4%) is available to prescribe in the US.¹

The topical ophthalmic solution is preservative-free, packaged in single-use vials, and includes dual lubricants—hyaluronic acid and hydroxypropyl methylcellulose—for patient comfort.¹ Patients can enjoy the flexibility of using a single drop per eye for improved near vision for a specific occasion or activity, or up to 2 drops daily for an extended effect lasting up to 8 hours. Prescriptions can be filled through BlinkRx or Medvantx, with free home delivery.

The product’s proprietary EyeQ Formulation is designed to maximize efficacy while minimizing side effects. This is achieved by balancing the lowest approved concentration of pilocarpine at a near-neutral pH for optimal bioavailability.1

“We are proud to deliver [pilocarpine hydrochloride ophthalmic solution 0.4%], a solution that ushers in a new era in near vision correction and aims to empower patients,” said Elad Kedar, chief executive officer of Orasis Pharmaceuticals. “Our goal has always been to improve near vision for the millions of people struggling with presbyopia, give them a break from readers, and provide eye care professionals with an additional option to optimize care for their patients.”

“When it comes to pharmacologic agents for refractive correction treatments for presbyopia, formulation matters,” noted Richard L. Lindstrom, MD, founder and attending surgeon of Minnesota Eye Consultants and adjunct professor emeritus at the University of Minnesota Department of Ophthalmology, speaking to Ophthalmology Times.

“As we’ve seen with other ophthalmic treatments, even small adjustments in formulation can have a significant impact on efficacy, safety, and tolerability. Products like Qlosi, with its EyeQ Formulation, which minimizes pilocarpine concentrations and closely matches the pH of natural tears, offers a compelling and patient-friendly treatment option,” Lindstrom added.

The FDA approval of the treatment in October 2023 was based on the results from two pivotal Phase 3 clinical trials, NEAR-1 and NEAR-2 (NCT04599933​ and NCT04599972), which evaluated its efficacy, safety, and tolerability in more than 600 adult patients with presbyopia. Both trials met their primary and key secondary end points on Day 8, achieving statistically significant 3-line or more gain in distance-corrected near visual acuity and no loss of 1-line or more in distance visual acuity. Patients with presbyopia achieved their best results when taking the eye drop consecutively over 2 weeks. All adverse events reported were in the single digits, with headache (6.8%) and instillation site pain (5.8%) being the most commonly reported treatment-related adverse events.2,3,4

The website www.QlosiECP.com provides resources for both patients and eye care providers, including guidance on usage and details about the Qlosi Clear Start Kit, which is included with the first prescription for each patient.

References
  1. Orasis Pharmaceuticals announces novel corrective eyedrop for presbyopia, Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4%, now available to prescribe in the U.S. News release. Orasis Pharmaceuticals. April 7, 2025. Accessed April 7, 2025. https://www.orasis-pharma.com/orasis-pharmaceuticals-strengthens-leadership-team-with-key-hires-to-support-the-launch-of-qlosi-pilocarpine-hydrochloride-ophthalmic-solution-0-4/
  2. Orasis Pharmaceuticals announces FDA approval of Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4% for the treatment of presbyopia. News release. Orasis Pharmaceuticals. October 18, 2023. Accessed April 7, 2025. https://www.orasis-pharma.com/orasis-pharmaceuticals-announces-fda-approval-of-qlosi-pilocarpine-hydrochloride-ophthalmic-solution-0-4-for-the-treatment-of-presbyopia/
  3. Holland E, Karpecki P, Fingeret M, et al. Efficacy and safety of CSF-1 (0.4% pilocarpine hydrochloride) in presbyopia: pooled results of the NEAR Phase 3 randomized, clinical trials. Clin Ther. 2024;46(2):104-113. doi:10.1016/j.clinthera.2023.12.005
  4. Qlosi. Prescribing information. Orasis Pharmaceuticals; 2023. Accessed April 7, 2025. https://www.qlosi.com/hubfs/QLOSI%20NDA%20PI_Mar2024_QLO.00021.pdf

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Cranial nerve six palsy with chemosis is a critical clue to cavernous carotid fistula
(Image credit: Ophthalmology Times) Neda Shamie_Controversies in Modern Eye Care 2025
(Image credit: Ophthalmology Times) World Cornea Congress IX: Epi-on and accelerated crosslinking with Kenneth Beckman, MD
(Image credit: Ophthalmology Times) The synergy of cornea, cataract, and refractive surgery through the decades: insights from George O. Waring IV, MD
(Image credit: Ophthalmology Times) AGS 2025: A look at Gemini and the MIGS revolution with Mona Kaleem, MD
(Image credit: Ophthalmology Times) AGS 2025: Development and evaluation of an AI model to set target IOP with Jithin Yohannan, MD, MPH
(Image credit: Ophthalmology Times) NeuroOp Guru: The role of muscle biopsy in heteroplasmy detection
(Image credit: Ophthalmology Times) AGS 2025: Achieving success as an academic ophthalmologist with Thomas V. Johnson III, MD, PhD
(Image credit: Ophthalmology Times) AGS 2025: Constance Okeke, MD, highlights 1-year Streamline canaloplasty outcomes
(Image credit: Ophthalmology Times) AGS 2025: Telemedicine and genetics for resource-efficient care with Louis R. Pasquale, MD
© 2025 MJH Life Sciences

All rights reserved.